Shield Therapeutics plc (LON:STX - Get Free Report) traded up 9.5% during trading on Tuesday . The company traded as high as GBX 6.50 ($0.09) and last traded at GBX 6.15 ($0.08). 5,994,874 shares changed hands during trading, an increase of 174% from the average session volume of 2,189,812 shares. The stock had previously closed at GBX 5.61 ($0.08).
Shield Therapeutics Stock Performance
The stock has a market cap of £81.42 million, a P/E ratio of -2.13 and a beta of 1.42. The company has a debt-to-equity ratio of 3,691.50, a current ratio of 1.05 and a quick ratio of 2.16. The firm's 50-day moving average price is GBX 4.01 and its 200-day moving average price is GBX 3.24.
Shield Therapeutics Company Profile
(
Get Free Report)
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Featured Articles
Before you consider Shield Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.
While Shield Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access